Related Experiment Video
Updated: Apr 28, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
[Survival of patients with diffuse large B-cell lymphoma]
Arnoldo Salas-Delgado1, Marco Antonio Hernández-Pliego
1Servicio de Medicina Interna, Hospital de Especialidades 25, Instituto Mexicano del Seguro Social, Monterrey, Nuevo León, México. markaxo@hotmail.com.
Background:
The overall survival and relapse-free survival have increased with current chemotherapy in patients with non-lymphoma Hodgkin. A useful tool to evaluate projections is the International Prognostic Index. Our aim was to evaluate the relation between the prognosis established with the International Prognostic Index and the survival obtained in two years by patients with diffuse large B-cell lymphoma.
Methods:
An observational, longitudinal, prospective study was carried out. Patients included were those with diagnosis and treated along a year, who, at some point in their evolution, required hospitalization. All the patients received ciclofosfamide, doxorrubicine, vincristine and prednisone; additionally, some of them received rituximab. The follow-up average was 26 months. Survival was estimated with Kaplan-Meier curves.
Results:
Forty-nine patients were included and classified according to the International Prognostic Index risk. The survival was 90 % for patients with International Prognostic Index low risk, 66.7 % for the patients with intermediate-low risk, 80 % for patients with intermediate-high risk, and 81 % for patients with high risk. The survival for all risk groups was 77.6 %. When we compared the survival of patients with the expected prognosis through the International Prognostic Index, we obtained p = 0.0000.
Conclusions:
Two years after diagnosis, the survival of patients with diffuse large B-cell lymphoma in the study was better than the prognosis estimated through the International Prognostic Index, and similar to that reported in American studies.
